These results are elucidated by upregulated β‐catenin expression and Twist/Akt2 signaling: Twist/Akt2 signaling mediates paclitaxel resistance through enhancing mesenchymal markers and maintaining tumor cells with cancer stem cell‐like properties.77 This evidence concerns the gene TWIST1 and neoplasm.